newsfilter
← Latest News
GlobeNewswire·

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre